List of publications by chronological order

Mirko Beljanski’s breakthrough discoveries are all gathered in the scientist’s 133 publications available below:

  1. A propos du microdosage du ribose dans les acides nucléiques et leurs dérivés”:
    • M. BELJANSKI, M. MACHEBOEUF, C.R. Soc. Biol. 1949, CXLIII, pp. 174-175.
    • M. BELJANSKI, Ann. Inst. Pasteur, 1949, 76, pp. 451-455.
  2. F. GROS, M. BELJANSKI, M. MACHEBOEUF, F. GRUMBACH, “Comparaison biochimique d’une souche bactérienne sensible à la streptomycine avec une souche résistance de même espèce“. C.R. Acad. Sci., 1950, 230, pp.875-877.
  3. F. GROS, M. BELJANSKI, M. MACHEBOEUF, “Mode d’action de la pénicilline chez Staphylococcus aureus. Inhibition d’un système enzymatique extrait des bactéries“. C.R. Acad. Sci., 1950, 231, pp. 184-186.
  4. F. GROS, M. BELJANSKI, M. MACHEBOEUF, “Action de la pénicilline sur le métabolisme de l’acide ribonucléique chez Staphylococcus aureus “. Bull. Soc. Chim. Biol., 1951, 33, pp. 1696-1717.
  5. F. GROS, M. BELJANSKI, M. MACHEBOEUF, F. GRUMBACH, F.BOYER, “Activité biologique des combinaisons streptomycine-acides gras“. C. R. Acad., Sci., 1951, 232, pp. 764-766.
  6. M. BELJANSKI, “Etudes de souches bactériennes résistantes à des antibiotiques. Comparaison avec des souches sensibles de mêmes espèces“. Ann. Biol., 1951, 27, pp. 775-780.
  7. M. BELJANSKI, ”Etudes de souches bactériennes résistantes à des antibiotiques. Comparaison avec des souches sensibles de mêmes espèces“. Thèse de Doctorat ès Sciences d’Etat, Université Paris-la Sorbonne, 1951, Paris, Librairie Arnette, 1952.
  8. M. BELJANSKI, “Action de la cocarboxylase sur le métabolisme des acides nucléiques chez Staphylococcus aureus sensible et résistant à la streptomycine“. 2ème Congrès Intern. de Biochimie, Paris, 1952. Résumé des communications,99.
  9. M. BELJANSKI, “Comparaison de souches bactériennes résistantes à des antibiotiques avec des souches sensibles de même espèce -I : Cas de la streptomycine“. Ann. Inst. Pasteur, 1952, 83, pp. 80-101.
  10. M. BELJANSKI, “Comparaison de souches bactériennes résistantes à des antibiotiques avec des souches sensibles de même espèce – II : Cas de la pénicilline“. Ann. Inst. Pasteur, 1953, 84, pp. 402-409.
  11. M. BELJANSKI, “Comparaison de souches bactériennes résistantes à des antibiotiques avec des souches sensibles de même espèce -III : Cas du sulfamide – IV : Cas de l’azoture de sodium“. Ann. Inst. Pasteur, 1953, 84, pp. 756-764.
  12. M. BELJANSKI, “Comparaison de souches bactériennes résistant à la streptomycine avec des souches sensibles de même espèce“. C.R. Acad. Sci., 1953, 236, pp. 1102-1104.
  13. M. BELJANSKI, F. GRUMBACH, “Etude biochimique d’une souche de Mycobacterium tuberculosis streptomycino-sensible et d’une souche streptomycino-résistance dérivée de la souche sensible“. C.R. Acad., Sci., 1953, 236, pp. 2111-2114.
  14. M. BELJANSKI, “Etude des acides nucléiques de souches bactériennes résistantes à la streptomycine et de souches de mêmes espèces mais sensibles à l’antibiotique“. Ann. Inst. Pasteur, 1953, 85, pp. 463-469.
  15. M. BELJANSKI, J.GUELFI, “Etude à l’aide du 32P de l’accumulation des acides nucléiques chez Staphylococcus aureus et Salmonella enteritidis résistants et sensibles à la streptomycine“. Ann. Inst. Pasteur, 1954, 86, pp. 115-117.
  16. M. BELJANSKI, “L’absence de cytochromes et de certains systèmes enzymatiques dans un nouveau mutant d’Escherichia coli streptomycino-résistant. Comparaison avec la souche sensible dont il dérive“. C.R. Acad., Sci., 1954, 238, pp. 852-854.
  17. M. BELJANSKI, “L’action de la ribonuéclase et de la désoxyribonucléase sur l’incorporation de glycocolle radioactif dans les protéines de lysats de Micrococcus lysodeikticus“. Biochim. Biophys. Acta. 15, 99. pp. 425-431.
  18. M. BELJANSKI, “Isolement de mutants d’Escherichia coli streptomycino-résistants dépourvus d’enzymes respiratoires. Action de l’hémine sur la formation de ces enzymes chez le mutant H-7“. C.R. Acad., Sci., 1955, 240, pp. 374-376.
  19. M. BELJANSKI, ”Formation d’enzymes respiratoires chez un mutant d’Escherichia coli streptomycino-résistant ne manifestant pas d’activité respiratoire“. 3ème Congrès Intern. Biochim., Bruxelles, 1955, p 98 – Résumés des communications.
  20. R. LATARJET, M. BELJANSKI, ”Photorestoration in porphyrin-less mutants of Escherichia coli“. Microbial Genetic Bulletin, E. Witkin, 1955 – Résumés.
  21. M. BELJANSKI, “Reconstitution in vitro de la catalase“. C.R. Acad., Sci., 1955, 241, pp. 1353-1355.
  22. R. LATARJET, M. BELJANSKI, “Photo-restauration de bactéries dépourvues de porphyrines“. Ann. Inst. Pasteur, 1956, 90, pp. 127-132.
  23. M. BELJANSKI, M. S. BELJANSKI, “Sur la formation d’enzymes respiratoires chez un mutant d’Escherichia coli streptomycino-résistant et auxotrophe pour l’hémine“. Ann. Inst. Pasteur, 1957, 92, pp. 396-412.
  24. M. BELJANSKI, S. OCHOA, “Protein biosynthesis by a cell-free bacterial system” Proc. Nat. Acad. Sci. Biochemistry, 1958,44, pp. 494-501.
  25. M. BELJANSKI, M. S. BELJANSKI, VII-ème Congrès Intern. de Microbiol. Stockolm, 1958, Symposium, II. Discussions.
  26. M. BELJANSKI, S. OCHOA, “Protein biosynthesis by a cell-free bacterial system” IV-ème Congrès Intern. Biochim. Vienne, 1958, p.49 – Résumés des commnunications.
  27. M. BELJANSKI, S. OCHOA, “Protein bio-synthesis by a cell-free bacterial system. II-Further studies on the amino acid incorporation enzyme”. Proc. Nat. Acad. Sci., 1958,44, pp. 1157-1161.
  28. M. BELJANSKI, “Identification de quatre kinases spécifiques des diphosphonucléosides dans une préparation enzymatique d’origine bactérienne“. C.R. Acad. Sci., 1959, 248,pp. 1146-1448.
  29. M. BELJANSKI, “Synthèse de peptides par un système enzymatique en présence de nucléoside – triphosphates“. C.R. Acad. Sci., 1960, 250,pp.624-626.
  30. M. BELJANSKI, “Protein biosynthesis by a cell-free bacterial system. III- Determination of new peptide bonds; requirement for the “amino acid incorporation enzyme” in protein biosynthesis” Biochim. Biophys. Acta., 1960, 41, pp. 104-110.
  31. M. BELJANSKI, “Protein biosynthesis by a cell-free bacterial system. IV- Exchange of diphosphonucleosides with homologous triphosphonucleosides by the “amino acid incorporation enzyme“. Biochim. Biophys. Acta., 1960,41, pp.111-115.
  32. M. BELJANSKI, “Ribonucleoside-5′-triphosphate dependent synthesis of peptides by the purified amino acid incorporation enzyme”. Progress in Biophysics and Biophysical Chemistry, Pergamon Press, 1961, 11, p. 238.
  33. M. BELJANSKI, “Ribonucléosidetriphosphates et synthèses de peptides spécifiques par des enzymes purifiés“. Bull. Soc. Chim. Biol., 1961,43, pp.1017-1030.
  34. M. BELJANSKI, ”Ribonucléoside-triphosphates et synthèse enzymatique de liaisons peptidiques“. Symposium sur les Acides Ribonucléiques et les Polyphosphates “. C.N.R.S., 1961,pp. 474-475.
  35. M. BELJANSKI, M. S. BELJANSKI, ”Synthèses de peptides spécifiques par un système enzymatique purifié d’Alcaligenes faecalis“. Vème Congrès Intern. Biochim. Moscou, 1961,p.24.
  36. M. BELJANSKI, Discussions, Symposium sur la Biosynthèse des Protéines. Vème Congrès Intern. Biochim. Moscou, 1961.
  37. J.P. ZALTA, M. BELJANSKI, “Synthèse de peptides par des fractions subcellulaires préparées à partir du foie de Rat“. C.R. Acad. Sci. 1961, 253, pp.567-569
  38. M. BELJANSKI, M. S. BELJANSKI, T. LOVINY, “Rôle des polypeptide-synthétases dans la formation de peptides spécifiques en présence de ribonucléoside triphosphates“. Biochim. Biophys. Acta., 1962, 56, pp. 559-570.
  39. M. BELJANSKI, “Participation of an RNA fraction in peptide synthesis in the presence of a purified enzyme system from Alcaligenes faecalis“. Biochim. Biophys. Res. Comm., 1962, 8, pp. 15-19.
  40. M. BELJANSKI, M. S. BELJANSKI, ”Acide aminé – acide ribonucléique” , intermédiare dans la synthèse des liaisons peptidiques“. VI- Biochim. Biophys. Acta., 1963, 72, pp. 585-597.
  41. M. BELJANSKI, “ARN-messager: intermédiaire direct dans la synthèse des liaisons peptidiques“. Colloques Internationaux du C.N.R.S., Marseille, 1963, pp. 39-44. (Mécanismes de régulation des activités cellulaires chez les micro-organismes).
  42. M. BELJANSKI, C. FISHER, M. S. BELJANSKI, “Le RNA messager, accepteur spécifique des L-acides aminés en présence d’enzymes bactériennes“. C.R. Acad. Sci., 1963,257, pp. 547-550.
  43. M. BELJANSKI, C. FISHER, “Les ARN messagers” gouvernant la synthèse ” in vitro ” des chaînes peptidiques en présence de “polypeptides synthétases”. Pathologie-Biologie, 1965,13, pp. 198-203.
  44. M. BELJANSKI, “Messenger RNA Dependent Synthesis of Peptides by Purified Bacterial Enzymes”. Bioch-Zeits, 1965, 342, pp. 392-399.
  45. M. BELJANSKI, “L’ARN isolé du virus de la mosaïque jaune du Navet, accepteur des L-acides aminés en présence d’enzymes bactériennes“. Bull. Soc. Chim. Biol. 1965, 47, pp. 1645-1652.
  46. M. BELJANSKI, N. VAPAILLE, “Rôle des triterpènes dans l’attachement des l-acides aminés par des ” ARN matriciels”“. Eur. J. of Clin. Biol. Res., 1971, pp. 897-908.
  47. M. BELJANSKI, P. BOURGAREL, “Isolement de di- et trinucléotides, sites spécifiques d’attachement d’arginine et de valine dans des ARN d’ origine différente“. C.R. Acad. Sci., 1967,264, pp. 1760-1763 (série D).
  48. M. BELJANSKI, C. FISCHER-FERRARO, “Nouvelle méthode de purification des polypeptides-synthétases“. C.R. Acad. Sci., 1967,264, pp. 411-414 (série D).
  49. M. BELJANSKI, C. FISCHER-FERRARO, P. BOURGAREL, ”Identification des sites d’attachement spécifiques d’arginine et de valine dans des ARN d’ origines différentes“. VIII- European J. Biochem., 1968,4, pp. 184-189.
  50. C. FISCHER-FERRARO, M. BELJANSKI, “Nouvelle méthode de purification des polypeptides synthétases“. VII- European J. Biochem., 1968, 4, pp. 118-125.
  51. M. BELJANSKI, P. BOURGAREL, “Isolement et caractérisation d’un RNA matriciel d’Alcaligenes faecalis“. C.R. Acad. Sci., 1968, 266, pp. 845-847
  52. M. BELJANSKI, M.S. BELJANSKI, ”Synthèse dans Escherichia coli des ARN dont la structure primaire diffère totalement de celle de l’ADN“. C.R. Acad. Sci., 1968, 267, pp. 1058-1060 (série D).
  53. M. BELJANSKI, M.S. BELJANSKI, P. BOURGAREL, J. CHASSAGNE, ”Synthèse chez les bactéries d’ARN nouveaux n’étant pas la copie de l’ADN“. C.R. Acad. Sci., 1969, 269, pp. 240-243 (série D).
  54. M. BELJANSKI, P. BOURGAREL, M.S. BELJANSKI, ”Showdomycine et biosynthèse d’ARN non complémentaires de l’ADN” – I __ Ann. Inst. Pasteur, 1970, 118, pp. 253-276
  55. M. BELJANSKI, P. BOURGAREL, M.S. BELJANSKI, “Drastic Alteration of Ribosomal RNA and Ribosomal Proteins in Showdomycin-Resistant Escherichia Coli”. Proc. Nat. Aca. Sci. (USA), 1971, 68, pp. 491-495.
  56. M. PLAWECKI, M. BELJANSKI, “Transcription par la polynucleotide phosphorylase de l’ARN associé à l’ADN d’Escherichia coli“. C.R. Acad. Sci., 1971, 273, pp. 827-830 (série D).
  57. M. BELJANSKI, M.S. BELJANSKI, P. BOURGAREL, “ARN transformants porteurs de caractères héréditaires chez Escherichia coli showdomycino-résistant“. C.R. Acad. Sci., 1971, 272, pp. 2107-2110 (série D).
  58. M. BELJANSKI, M.S. BELJANSKI, P. BOURGAREL, ” ” Episome à ARN ” porté par l’ADN d’Escherichia coli sauvage et showdomycino-résistant “. C.R. Acad. Sci., 1971, 272, pp. 2736-2739 (série D).
  59. M. BELJANSKI, M.S. BELJANSKI, P. MANIGAULT, P. BOURGAREL, “Transformation of Agrobacterium tumefaciens into a Non-oncogenic Species by an Escheria coli RNAM” Proc. Nat. Aca. Sci. (USA), 1972, 69, pp. 191-195.
  60. M. BELJANSKI, “Synthèse in vitro de l’ADN sur une matrice d’ARN par une transcriptase d’Escherichia coli“. C.R. Acad. Sci., 1972,274, pp. 2801-2804 (série D).
  61. M. BELJANSKI, C. BONISSOL, P. KONA, “Transformation des cellules K.B. induite par la showdomycine“. C.R. Acad. Sci., 1972, 274, pp. 3116-3119 (série D).
  62. M. BELJANSKI, P. MANIGAULT, “Genetic transformation of bacteria by RNA and loss of oncogenic power properties of Agrobacterium tumefaciens. Transforming RNA as template for DNA synthesis“. Sixth International Symposium on Molecular Biology. Ed.F.Beers and R.C.Tilghman. The John Hopkins University Press, Baltimore, 1972, pp. 81-97.
  63. M. BELJANSKI, “Séparation de la transcriptase inverse de l’ADN polymérase ADN dépendante. Analyse de l’ADN synthétisé sur le modèle de l’ARN transformant“. C.R. Acad. Sci., 1973, 276, pp. 1625-1628 (série D).
  64. M. BELJANSKI, M. PLAWECKI, “Transforming RNA as a template directing RNA and DNA synthesis in bacteria“. In Niu and Segal (eds), The Role of RNA in reproduction and development. North Holland Publ.Co., 1973, pp.203-224.
  65. M. PLAWECKI, M. BELJANSKI, “Synthèse in vitro d’un ARN utilisé comme amorceur pour la réplication de l’ADN“. C.R. Acad. Sci., 1974, 278, pp. 1413-1416 (série D).
  66. M. BELJANSKI, Y. AARON-DA-CUNHA, M.S. BELJANSKI, P. MANIGAULT, P. BOURGAREL, “Isolation of the Tumor-Inducing RNA from Oncogenic and Nononcogenic Agrobacterium tumefaciens”. Proc. Nat. Acad. Sci. (USA), 1974, 71, pp. 1585-1589.
  67. M. BELJANSKI, M.S. BELJANSKI, ”RNA-Bound Reverse Transcriptase in Escherichia coli and in Vitro Synthesis of a Complementary DNA“. Biochemical genetics, 1974, 12, pp. 163-180.
  68. M. BELJANSKI, P. MANIGAULT, M.S. BELJANSKI, Y. AARON-DA-CUNHA, “Genetic transformation of Agrobacterium tumefaciens B6 by RNA and nature of the tumor-inducing principle”. First Intern. Congress of the Intern. Assoc. of Microbiol. Soc. Tokyo I.A.M.S., 1974,1, pp. 131-141.
  69. M. BELJANSKI, M. S. BELJANSKI, M. PLAWECKI, P. MANIGAULT, “ARN-fragments, amorceurs nécessaires à la réplication ” in vitro ” des ADN“. C.R. Acad. Sci., 1975, 280, pp. 363-366 (série D).
  70. M. BELJANSKI, L. CHAUMONT, C. BONISSOL, M. S. BELJANSKI, ”ARN-fragments inhibiteurs ” in vivo ” de la multiplication des virus du fibrome de Shope et de la vaccine” C.R. Acad. Sci., 1975, 280, pp. 783-789 (série D).
  71. M. BELJANSKI, “ARN-amorceurs riches en nucléotides G et A indispensables à la réplication in vitro de l’ADN des phages QX174 et lambda (_)“. C.R. Acad. Sci., 1975, 280, pp. 1189-1192 (série D).
  72. L. LE GOFF, Y. AARON-DA-CUNHA, M. BELJANSKI, “RNA fraction from several nononcogenic strains of Agrobacterium tumefaciens as tumor inducing agent in Datura stramonium”. XIIth Intern. Bot. Congress. Résumés. Leningrad, 1975.
  73. M. BELJANSKI, Y. AARON-DA-CUNHA, “RNA fractions from other sources than Agrobacterium tumefaciens as tumor- inducing agent in Datura stramonium”. Workshop Third Intern. Congress of Virology, Madrid, 1975, p. 15.
  74. L. LE GOFF, Y. AARON-DA-CUNHA, M. BELJANSKI, ”Un ARN extrait d’Agrobacterium tumefaciens souches oncogènes et non oncogènes, élément indispensable à l’induction des tumeurs chez Datura stramonium“. Canadian J. of microbiology, 1976, 22, pp. 694-700.
  75. M. BELJANSKI, Y. AARON-DA-CUNHA, “Particular small size RNA and RNA fragments from different origins as tumor inducing agents in Datura stramonium“. Molec. Biol. Reports, 1976, 2, pp. 497-506.
  76. S.K. DUTTA, M. BELJANSKI, P. BOURGAREL, “Endogenous RNA-Bound RNA Dependent DNA Polymerase Activity in Neurospora crassa“. Exp. Mycology, 1977, 1, pp. 173-182.
  77. L. LE GOFF, Y. AARON-DA-CUNHA, M. BELJANSKI, ”Polyribonucleotides, agents inducteurs et inhibiteurs des tissus tumoraux“. Conf. Intern. Montpellier (1978) – Résumés.
  78. M. BELJANSKI, P. BOURGAREL, M.S. BELJANSKI, “Découpage des ARN ribosomiques d’Escherichia coli par la ribonucléase U2 et transcription in vitro des “ARN-fragments” en ADN complémentaire“. C.R. Acad. Sci., 1978, 286, pp. 1825-1828 (série D).
  79. M. BELJANSKI, M. PLAWECKI, P. BOURGAREL, M. S. BELJANSKI, “Nouvelles substances (R.L.B.) actives dans la leucopoïese et la formation des plaquettes“. Bull. Acad. Nat. Med., 1978, 162, Volume n°6, pp. 475-781.
  80. M. STROUN, Ph. ANKER, M. BELJANSKI, J. HENRI, Ch. LEDERREY, M. OJHA, P. MAURICE, “Presence of RNA in the Nucleoprotein Complex Spontaneously Released by Human Lymphocytes and Frog Auricles in Culture”. Cancer Res., 1978, 38, pp. 3546-3554.
  81. M. BELJANSKI, L. LE GOFF, Y. AARON-DA-CUNHA, “Special short dual-action RNA fragments can both induce and inhibit crown-gall tumors”. Proc. 4th Conf. Plant Path. Bacteria, Angers, 1978, pp. 207-220.
  82. M. BELJANSKI, L. LE GOFF, ”Stimulation de l’induction – ou inhibition du développement – des tumeurs de Crown-gall par des ARN-fragments U2. Interférence de l’auxine“. C.R. Acad. Sci., 1979, 288, pp. 147-150 (série D).
  83. M. BELJANSKI, M. PLAWECKI, “Particular RNA Fragments as Promoters of Leukocyte and Platelet Formations in Rabbits“. Exp. Cell Biol., 1979, 47, pp. 218-225.
  84. M. BELJANSKI, “Oncotest: a DNA assay system for the screening of carcinogenic substances“. IRCS Medical science, 1979, 7, pp. 476.
  85. L. LE GOFF, M. BELJANSKI, “Cancer/anti-cancer dual action drugs in crown-gall tumors“. IRCS Medical Science, 1979, 7, p. 475.
  86. M. BELJANSKI, “Oligoribo-nucleotides, promoters of leucocyte and platelet genesis in animals depleted by anticancer drugs”. NCI-EORTC Symposium on nature, prevention and treatment of clinical toxicity of anticancer agents. Institut Bordet, Bruxelles, 1980.
  87. M. BELJANSKI, M. PLAWECKI, P. BOURGAREL, M.S. BELJANSKI, “Short chain RNA fragments as promoters of leucocyte and platelet genesis in animals depleted by anti-cancer drugs”. In the Role of RNA in Development and Reproduction. Sec. Int. Symposium, april 25-30, 1980, pp.79-113. Science Press Beijing. M.C. Niu and H.H. Chuang Eds Van Nostrand Reinhold Company.
  88. M. BELJANSKI, P. BOURGAREL, M.S. BELJANSKI, “Correlation between in vitro DNA Synthesis, DNA Strand Separation and in vivo Multiplication of Cancer Cells“. Expl. Cell. Biol., 49, 1981, pp. 220-231.
  89. M. PLAWECKI, M. BELJANSKI, “Comparative Study of Escherichia coli Endotoxin, Hydrocortisone and Beljanski Leucocyte Restorer Activity in Cyclophosphamide-Treated Rabbits”. Proc. of the Soc. for Exp. Biol. and Med., 168, 1981, pp. 408-413
  90. M. BELJANSKI, L. LE GOFF, M.S. BELJANSKI, “Differential susceptibility of cancer and normal DNA templates allows the detection of carcinogens and anticancer drugs“. Third NCI-EORTC Symp. on new drugs in Cancer therapy, Institut Bordet, Bruxelles, 1981.
  91. L. LE GOFF, M. BELJANSKI, “Crown-gall Tumor Stimulation or Inhibition: Correlation with DNA Strand Separation“. Proc. Fifth Int. Conf. Plant Path. Bact. Cali, 1981, p. 295-307.
  92. M. BELJANSKI, M.S. BELJANSKI, “Selective Inhibition of in vitro Synthesis of Cancer DNA by Alkaloids of ß-Carboline Class“. Expl. Cell. Biol., 50, 1982, pp. 79-87.
  93. L. LE GOFF, M. BELJANSKI, “Agonist and/or antagonists effects of plant hormones and an anticancer alkaloid on plant DNA structure and activity” IRCS Med. Sci., 10, 1982, pp. 689-690.
  94. M. BELJANSKI, L. LE GOFF, A. FAIVRE-AMIOT, ”Preventive and curative anticancer drug. Application to Crown-gall tumors” Acta Horticulturae, n°125, 1982, pp. 239-248.
  95. M. BELJANSKI, ” Oncotest: dépistage des potentiels cancérogènes et spécifiquement anti-cancéreux. Conceptions et perspectives nouvelles en cancérologie “. Environnement et nouvelle médecine. n°2, 1982, pp. 18-23.
  96. M. BELJANSKI, L. LE GOFF, M. S. BELJANSKI, ”In vitro Screening of Carcinogens Using DNA of the His- Mutant of Salmonella typhimurium“. Expl. Cell. Biol., 50, 1982, pp. 271-280.
  97. M. BELJANSKI, L. LE GOFF, “Tumor promoter (TPA), DNA chain opening and unscheduled DNA synthesis“. IRCS Med. Sci., 11, 1983, pp. 363-364.
  98. M. BELJANSKI, M. PLAWECKI, P. BOURGAREL, M.S. BELJANSKI, ”Leucocyte Recovery With Short-Chain RNA Fragments in Cyclophosphamide-Treated Rabbits“. Cancer Treatment Reports, 67, 1983, pp. 611-619.
  99. M. BELJANSKI, “The Regulation of DNA Replication and Transcription. The Role of Trigger Molecules in Normal and Malignant Gene Expression“. Experimental Biology and Medicine, vol.8, Karger (1983), pp. 1-190.
  100. M. BELJANSKI, M.S. BELJANSKI, “Three alkaloids as selective destroyers of the proliferative capacity of cancer cells“. IRCS Med. Sci., 12, 1984, pp. 587-588.
  101. L. LE GOFF, J. ROUSSAUX, Y. AARON-DA-CUNHA, M. BELJANSKI, ”Growth inhibition of crown-gall tissues in relation to the struture and activity of DNA” Physiol. Plant., 64, 1985, pp. 177-184.
  102. L. LE GOFF, M. BELJANSKI, “The in vitro Effects of Opines and Other Compounds on DNAs Originating from Bacteria and from Healthy and Tumorous Plant Tissues“. Expl. Cell. Biol., 53, 1985, pp. 335-350.
  103. M. BELJANSKI, ”Activation et inactivation des gènes: Incidence en cancérologie“. Aspect de la recherche. Université Paris-Sud, 1985, pp. 56-62
  104. M. BELJANSKI, M.S. BELJANSKI, ”Three Alkaloids as Selective Destroyers of Cancer Cells in Mice. Synergy with Classic Anticancer Drugs“. Oncology, 43, 1986, pp. 198-203.
  105. M. BELJANSKI, L. LE GOFF, ”Analysis of small RNA species: phylogenetic trends“. In DNA Systematics, vol.I: Evolution. Ed. S.K. Dutta CRC Press, Inc. Florida (1986), pp. 81-105.
  106. M. BELJANSKI, T. NAWROCKI, L. LE GOFF, “Possible role of markers synthesized during cancer evolution: I- Markers in mammalian tissues“. IRCS Med. Sci. 14, 1986, pp. 809-810.
  107. L. LE GOFF, M. BELJANSKI, “Possible role of markers synthesized during cancer evolution: II- Markers in crown-gall tissues”. IRCS Med. Sci. 14, 1986, pp. 811-812.
  108. M. BELJANSKI, L. LE GOFF, M.S. BELJANSKI, ”Régulation des gènes, cancer et prévention“. Médecines nouvelles, 15, 1986, pp. 57-86.
  109. M. BELJANSKI, ”Terminal deoxynucleotidyl transferase and ribonuclease activities in purified hepatitis-B antigen“. Med. Sci. Res., 15, 1987, pp. 529-530.
  110. M. BELJANSKI, S.K. DUTTA, “Differential Synthesis and Replication of DNA in the Neurospora crassa Slime Mutant versus Normal Cells: Role of Carcinogens“. Oncology, 44, 1987, pp. 327-330.
  111. S.K. DUTTA, M. BELJANSKI, “Particular RNA primer from growth medium differentially stimulates in vitro DNA synthesis and in vivo cell growth of Neurospora crassa and its slime mutant“. Current Genetics, 12, 1987, pp. 283-289.
  112. M. BELJANSKI, L.C. NIU, M.S. BELJANSKI, S. YAN, M.C. NIU, “Iron stimulated RNA-dependent DNA polymerase Activity from goldfish eggs”. Cellular and Molecular Biology, 34, 1988, pp. 17-25.
  113. L. LE GOFF, M. WICKER, M. BELJANSKI, “Reversible biophysical changes of DNAs from in vitro cultured non-tumour cells“. Med. Sci. Res., 16, 1988, pp. 359-361.
  114. M. STROUN, P. ANKER, P. MAURICE, J. LYAUTEY, C. LEDERREY, M. BELJANSKI, “Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients“. Oncology, 46, 1989, pp. 318-322.
  115. M. BELJANSKI, M.S. BELJANSKI, M. GRANDI “Resultati preliminari dell’impiego di tre alcaloidi nel carcinoma prostatico“. In Tumori, Institute Nationale per le studio ed la cura dei tumori (ed. Lambrosiana), Vol. 75, suppl. 4, 1989.
  116. M. BELJANSKI, “Cancer Therapy: A New Approach“. Deutsche Zeitschrift für Onkologie 5, 22, 1990, pp. 145-152.
  117. M. BELJANSKI, “Cancer et Sida. Nouvelles approches thérapeutiques”. 5èmes Entretiens Internationaux de Monaco, 21-24 novembre 1990 (ed. du Rocher), pp. 25-37.
  118. D. DONADIO, R. LORHO, J.E. CAUSSE, T. NAWROCKI, M. BELJANSKI,”RNA Fragments (RLB) and Tolerance of Cytostatic Treatments in Hematology: A Preliminary Study about Two Non-Hodgkin Malignant Lymphoma Cases“. Deutsche Zeitschrift für Onkologie, 23, 2, 1991, pp. 33-35.
  119. M. BELJANSKI, ”Reverse Transcriptases in Bacteria: Small RNAs as Genetic Vectors and Biological Modulators“. Brazil. J. Genetics, 14, 4, 1991, pp. 873-896.
  120. M. BELJANSKI, “Radioprotection of Irradiated Mice – Mechanisms and Synergistic Action of WR-2721 and R.L.B.”. Deutsche Zeitschrift für Onkologie, 23, 6, 1991, pp. 155-159.
  121. M. BELJANSKI, ”Overview: BLRs as Inducers of In Vivo Leucocyte and Platelet Genesis“. Deutsche Zeitschrift für Onkologie, 24, 2, 1992, pp. 41-46.
  122. M. BELJANSKI, ”A New Approach to Cancer Therapy“. Proceedings of the international seminar: Traditional Medicine: a Challenge of the 21st Century, 7-9 Nov. 1992, Calcutta (ed. in chief Biswapati Mukherjee).
  123. M. BELJANSKI, S. CROCHET, M.S. BELJANSKI, “PB100: A Potent and Selective Inhibitor of Human BCNU Resistant Glioblastoma Cell Multiplication“. Anticancer Research, vol.13, n°6A, Nov. Dec. 1993, pp. 2301-2308.
  124. M. BELJANSKI, S. CROCHET, “Differential effects of ferritin, calcium, zinc and gallic acid on in vitro proliferation of human glioblastoma cells and normal astrocytes“. J. Lab. Clin. Med. 123:547-555, 1994.
  125. M. BELJANSKI, S. CROCHET, “The selective anticancer agent PB-100 inhibits interleukin-6 induced enhancement of glioblastoma cell proliferation in vitro“. International Journal of Oncology, 5:873-879, 1994.
  126. M. BELJANSKI, S. CROCHET, ”Selective inhibitor (PB-100) of human glioblastoma cell multiplication“. Journal of Neuro-Oncology, Vol. 21, N°1, p. 62, 1994.
  127. J.E. CAUSSE, T. NAWROCKI, M. BELJANSKI, “Human Skin Fibrosis RNase Search for a Biological Inhibitor-Regulator“. Deutsche Zeitschrift für Onkologie, 26, 5, 1994, pp. 137-139.
  128. M. BELJANSKI, S. CROCHET, “The anticancer agent PB-100 concentrates in the nucleus and nucleoli of human glioblastoma cells but does not enter normal astrocytes“. International Journal of Oncology 7:81-85, 1995.
  129. M. BELJANSKI, “Novel selective nontoxic anticancer and antiviral agents“. International Journal of Oncology Vol. 7. supplement, p983, October 1995.
  130. M. BELJANSKI, S. CROCHET, “The selective anticancer agents PB-100 and BG-8 are active against human melanoma cells, but do not affect non malignant fibroblasts“. International Journal of Oncology 8:1143-1148, 1996.
  131. M. BELJANSKI, S. CROCHET, “Mitogenic Effect of Several Interleukins, Neuromediators and Hormones on Human Glioblastoma Cells, and its Inhibition by the Selective Anticancer Agent PB-100“. Deutsche Zeitschrift für Onkologie, 28, 1, 1996, pp. 14-22.
  132. M. BELJANSKI, “De Novo Synthesis of DNA – Like Molecules by Polynucleotide Phosphorylase In Vitro“. J. Mol. Evol. 1996, 42:493-499.
  133. M. BELJANSKI (posthume), “The anticancer Agent PB-100, Selectively Active on Malignant Cells, Inhibits Multiplication of Sixteen Malignant Cell Lines, even Multidrug Resistant“. Genetics and Molecular Biology 2000, vol 23 nº1, pp. 29.

133 – The anticancer Agent PB-100, Selectively Active on Malignant Cells, Inhibits Multiplication of 16 Malignant Cell Lines, even Multidrug Resistant

Authors : M. BELJANSKI (posthumous)
Genetics and Molecular Biology 2000, vol 23 nº1, pp. 29.

Available in English only

ABSTRACT IN ENGLISH: The plant-derived anticancer agent PB-100 (Beljanski® Pao extract) selectively destroys cancer cells, even when multidrug resistant; yet, it does not inhibit normal (non-malignant) cell multiplication. Testing of PB-100 on sixteen cell lines, several multidrug resistant, as well as on five normal cell lines, confirmed our previous results. Flavopereirine and dihydroflavopereirine, the active principles of PB-100, were chemically synthesized and displayed the same selectivity for tumor cells as the purified plant extract, being active at even lower concentrations.

List of cell lines tested : brain (4), ovary (2), breast (2), prostate thyroid (2), colon (2), pancreatic, hepatic, kidney, skin, liver

ABSTRACT IN PORTUGUES : O agente anticancerigeno de origem vegetal PB-100 destroi seletivamente as células cancerosas, mesmo quando elas sao resistentes a multiplas drogas; no entanto, ele nao inibe a multiplicacao de células normais (nao malignas). O teste do PB-100 em 16 linhagens de células malignas, assim como em 5 linhagens de células normais, confirmou nosso resultados prévios. Flavopereirine e dihidroflavopereirine, os principios ativos do PB-100, foram sintetizados quimicamente e mostraram a mesma seletividade para as células tumorais que o extrato purificado da planta, sendo ativos em concentraçoes ainda menores.

Download The anticancer Agent PB-100, Selectively Active on Malignant Cells, Inhibits Multiplication of 16 Malignant Cell Lines, even Multidrug Resistant

132 – De Novo Synthesis of DNA – Like Molecules by Polynucleotide Phosphorylase In Vitro

Authors : M. BELJANSKI
J. Mol. Evol. 1996, 42:493-499

Available in English only

ABSTRACT: In the presence of Mg2+ ions, polynucleotide phosphorylase (PNPase, EC 2.7.7.8) is known to synthesize RNA-like polymers using ribonucleoside-5′-diphosphate (NDP) substrates but to be unable to utilize deoxyribonucleoside substrates. Our experiments show that when MgCl2 is replaced by FeCl3, PNPase becomes able to synthesize deoxyheteropolymers using deoxyribonucleoside-5′-diphosphates (dNDPs). The deoxyheteropolymer formed from the four dNDPs is degraded by pancreatic DNase, but not by RNase, and is readily used as a template by DNA-dependent DNA polymerase. Synthesis of this DNA-like polymer is accomplished de novo without the help of any primer or preexisting template. What is more, dA/dG and dC/dT ratios of polymers synthesized by different bacterial PNPases closely match ratios found in DNA of the bacterial species the enzyme came from.

Download De Novo Synthesis of DNA – Like Molecules by Polynucleotide Phosphorylase In Vitro

131 – Mitogenic Effect of Several Interleukins, Neuromediators and Hormones on Human Glioblastoma Cells, and its Inhibition by the Selective Anticancer Agent PB-100

Authors : S. CROCHET, M. BELJANSKI
Deutsche Zeitschrift für Onkologie, 28, 1, 1996, pp. 14-22

Available in English only

ABSTRACT: We investigated in vitro the effect of six different substances present in the brain on two human cell lines: U251-BCNU-resistant glioblastoma cells, derived from a highly malignant cerebral tumor, and, as their normal counterparts, CRL 1656 astrocytes. The cytokines IL-4 and IL-10 (alone or together with IL-6), the catecholamine neuromediators dopamine and epinephrine, the steroid hormones progesterone and testosterone all significantly stimulated multiplication of the glioblastoma cells, but enhanced to a much lesses extent multiplication of normal astrocytes. The selective anticancer agent PB-100* inhibited these stimulatory effects. In addition, it could dose-dependently kill over 98% of the malignant cells while not affecting normal cells.

Download Mitogenic Effect of Several Interleukins, Neuromediators and Hormones on Human Glioblastoma Cells, and its Inhibition by the Selective Anticancer Agent PB-100

130 – The selective anticancer agents PB-100 and BG-8 are active against human melanoma cells, but do not affect non malignant fibroblasts

Authors : S. CROCHET, M. BELJANSKI
International Journal of Oncology 8:1143-1148, 1996

Available in English only

ABSTRACT: When past the stage amenable to surgery, melanoma and its metastases are, as a rule, treated with chemotherapy, which is largely unsuccessful. In this report, experimental evidence is presented demonstrating that, in vitro, two selective anticancer agents, PB-100 and BG-8, dose dependently destroy human G-361 melanoma cells, but do not affect human non malignant CCD-974Sk fibroblasts used as controls. Trace metal compounds, present, often in abnormal amounts, in the cancer cell and/or its environment, are known to influence its proliferation. Assays were carried out using highly elevated amounts of ferritin, iron chloride or zinc chloride. Ferritin proved differentially mitogenic for melanoma cells and fibroblasts. Its activity was inhibited by both anticancer agents, which however tended to become less efficacious in its presence. FeCl3 was more moderately, but equally, mitogenic for malignant and normal cells, yet it impaired antiproliferative activity of PB-100 and inhibited that of BG-8. ZnCl2 exhibited a selective antiproliferative activity on the malignant melanoma cells; it did not compete with PB-100 or BG-8. Specific recognition and destruction of malignant cells by the two anticancer agents are discussed.

Download The selective anticancer agents PB-100 and BG-8 are active against human melanoma cells, but do not affect non malignant fibroblasts

129 – Novel selective nontoxic anticancer and antiviral agents

Authors : M. BELJANSKI
International Journal of Oncology Vol. 7. supplement, p983, October 1995.

Available in English only

ABSTRACT: Selective targeting to diseased cells, ensuring nontoxicity for normal cells, are the master words for anticancer and antiviral therapies. Yet little progress has been made on these lines and adverse side effects are still the rule. After having designed a rapid and simple in vitro screening test (Oncotest), we were able to find a number of plant derived, chemically well defined substances which selectively inhibit cancer cell multiplication without affecting normal cells. Activity of these agents is based on the fact that, as we discovered after extensive comparison of DNAs from cancer cells and their normal counterparts, cancer DNA is characterized by its highly relaxed, destabilized secondary structure, within which H-bond breakage is evidenced by 260 nm UV absorption, always distinctly higher than that of normal DNA. Our anticancer agent easily bind to the “open” cancer DNA chains; in contrast, they do not bind to normal DNA chains, which are “closed” most of the time.

Download Novel selective nontoxic anticancer and antiviral agents

128 – The anticancer agent PB-100 concentrates in the nucleus and nucleoli of human glioblastoma cells but does not enter normal astrocytes

Authors : S. CROCHET, M. BELJANSKI
International Journal of Oncology 7:81-85, 1995.

Available in English only

ABSTRACT: Selectivity of the anticancer agent PB-100 for malignant cells, already demonstrated using cell growth and viability evaluation, is now confirmed by microscopic observations. PB-100 is easily detected inside cells by its yellow color under visible light and by its blue fluorescence; it may be measured in isolated nuclei using its characteristic UV absorbance. After short treatment of human BCNU-resistant glioblastoma cells (U 251) and normal astrocyte controls (CRL 1656), PB-100 accumulates in the malignant cell nucleus, particularly concentrating in the multiple nucleoli and rapidly inducing glioblastoma cell death, whilst, in contrast, the anticancer agent does not even enter normal cells. We had already shown that PB-100 binds to DNA of cancer cells, but not to that of normal cells. In vitro tests described in this report indicate that PB-100 binds to purine bases, but not to pyrimidines, of various ribopolymers and its binding to purine rich nucleic acid stretches is inferred.

Download The anticancer agent PB-100 concentrates in the nucleus and nucleoli of human glioblastoma cells but does not enter normal astrocytes

127 – Human Skin Fibrosis RNase Search for a Biological Inhibitor-Regulator

Authors : E. CAUSSE, T. NAWROCKI, M. BELJANSKI
Deutsche Zeitschrift für Onkologie, 26, 5, 1994, pp. 137-139.

Available in English only.

ABSTRACT: Human skin fibrosis caused by radiotherapy contains very active ribonucleases (RNasas). This is probably connected with the appearance of postradiotherapy fibrosis. We prepared a highly purified extract of Ginkgo biloba golden leaves, which behaves as biological regulator. It normalizes to a large extent the excessive RNase activity in an extract of irridiated human skin cells, but does not affect activity of normal human plasma RNase. This extract may be used for this fibrosis treatment.

Download Human Skin Fibrosis RNase Search for a Biological Inhibitor-Regulator

126 – Selective inhibitor (PB-100) of human glioblastoma cell multiplication

Authors : S. CROCHET, M. BELJANSKI
International Journal of Oncology, 5:873-879, 1994.

Available in English. French version available on request.

ABSTRACT: The multifunctional cytokine interleukin-6 behaves as a growth factor for various malignancies. It is produced in significant amounts by glioblastoma cells. When exogenous IL-6 is added (pg/ml) to culture medium of human glioblastoma cells and normal (non malignant) astrocytes used as controls, it exerts a dose dependent and differential effect on these two cell lines. Enhancement of cell proliferation is twice as high for glioblastoma cells as for astrocytes. In vitro, the novel anticancer agent PB-100 (mu g/ml) dose dependently inhibits this stimulatory activity. In addition, increasing PB-100 concentrations finally induce death of the malignant cells, yet do not impede multiplication of normal astrocytes. PB-100 does not abolish IL-6 production by cells, but keeps its level down to physiological values. PB-100 should therefore find its place in therapies requiring control of IL-6 production.

Download The selective anticancer agent PB-100 inhibits interleukin-6 induced enhancement of glioblastoma cell proliferation in vitr

125 – The selective anticancer agent PB-100 inhibits interleukin-6 induced enhancement of glioblastoma cell proliferation in vitro

Authors : M. BELJANSKI, S. CROCHET
International Journal of Oncology, 5:873-879, 1994.

Available online in English. French version upon request.

ABSTRACT: The multifunctional cytokine interleukin-6 behaves as a growth factor for various malignancies. It is produced in significant amounts by glioblastoma cells. When exogenous IL-6 is added (pg/ml) to culture medium of human glioblastoma cells and normal (non malignant) astrocytes used as controls, it exerts a dose dependent and differential effect on these two cell lines. Enhancement of cell proliferation is twice as high for glioblastoma cells as for astrocytes. In vitro, the novel anticancer agent PB-100 (mu g/ml) dose dependently inhibits this stimulatory activity. In addition, increasing PB-100 concentrations finally induce death of the malignant cells, yet do not impede multiplication of normal astrocytes. PB-100 does not abolish IL-6 production by cells, but keeps its level down to physiological values. PB-100 should therefore find its place in therapies requiring control of IL-6 production.

Download The selective anticancer agent PB-100 inhibits interleukin-6 induced enhancement of glioblastoma cell proliferation in vitro

124 – Differential effects of ferritin, calcium, zinc and gallic acid on in vitro proliferation of human glioblastoma cells and normal astrocytes

Authors : M. BELJANSKI, S. CROCHET
J. Lab. Clin. Med. 123:547-555, 1994.

Available in English only

ABSTRACT: In vitro, when using low concentrations of ferritin (ng/ml) or CaCl2 (micrograms/ml), multiplication of a human, 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)-resistant glioblastoma cell line (U251) is enhanced 1.5 to 2 times more actively than multiplication of a normal astrocyte line (CRL 1656). Ferritin and Ca2+ ions exhibit a marked effect on DNA isolated from these cells: glioblastoma DNA relaxation is strongly increased (as evidenced by increased 260 nm ultraviolet absorbance), being from 5 to 6 times that of astrocyte DNA, which remains only slightly affected. Under identical experimental conditions, Zn2+ and gallium ions selectively inhibit glioblastoma cell multiplication but at the same concentrations do not inhibit astrocyte multiplication. Ultraviolet absorbance measurements demonstrate that both of these agents condense relaxed glioblastoma DNA in vitro. Zn2+ or gallium ions added to culture medium containing stimulatory concentrations of ferritin or Ca2+ ions selectively and strongly inhibit enhancement of glioblastoma cell multiplication by these mitogens while not affecting normal multiplication of astrocytes.

Download Differential effects of ferritin, calcium, zinc and gallic acid on in vitro proliferation of human glioblastoma cells and normal astrocytes

123 – PB100: A Potent and Selective Inhibitor of Human BCNU Resistant Glioblastoma Cell Multiplication

Authors : M. BELJANSKI, S. CROCHET, M.S. BELJANSKI
Anticancer Research, vol.13, n°6A, Nov. Dec. 1993, pp. 2301-2308.

Available online in French, summary in English

ABSTRACT: Major drawbacks to present-day cancer chemotherapy are its intrinsic lack of selectivity for tumour cells, resulting in severe damage to normal rapidly dividing cells, and the widespread emergence of drug resistance. Here experimental evidence is presented demonstrating that PB-100, a beta-carboline alkaloid, selectively inhibits in vitro multiplication of human BCNU-resistant glioblastoma cells (U251), but has no effect on normal astrocyte (CRL 1656) multiplication. PB-100 activity is dose-dependent. In the presence of ferritin or CaCl2, which are highly mitogenic for glioblastoma cells, higher doses of the alkaloid are required to inhibit multiplication completely. PB-100 is one of several compounds which were selected for their specific action on cancer DNA and cells, together with lack of activity on normal DNA and cells. Both the selectivity of PB-100 and its ability to overcome drug resistance stem from its effect on cancer DNA secondary structure. This activity is described and discussed, and therapeutic applications are mentioned..

Download PB100: A Potent and Selective Inhibitor of Human BCNU Resistant Glioblastoma Cell Multiplication

122 – A New Approach to Cancer Therapy

Authors : M. BELJANSKI
Proceedings of the international seminar: Traditional Medicine: a Challenge of the 21st Century, 7-9 Nov. 1992, Calcutta (ed. in chief Biswapati Mukherjee).

Available in English only

ABSTRACT: Cell function and differentiation are the outcome of multiple and complex events. Information contained in the genes is transferred to the enzymes and machinery responsible for protein synthesis via sophisticated biochemical pathways, some of which, despite their intricacy, are now well documented. Conversely, genes receive information which modulates their activity. Many different molecules are able to bind to nucleic acids (deoxyribonucleic acid, DNA, and ribonucleic acid, RNA), thereby modifying gene activity as well as that of various enzymes connected with it. It is well established that the effect of endogenous or exogenous molecules on such fundamental processes of cell life as DNA duplication, transcription and translation may dramatically affect other biochemical processes both downstream and upstream. Binding of any molecule to DNA may influence cell life “for better or for worse”.

Download A New Approach to Cancer Therapy

120 – Radioprotection of Irradiated Mice – Mechanisms and Synergistic Action of WR-2721 and R.L.B.

Authors : M. BELJANSKI
Deutsche Zeitschrift für Onkologie, 23, 6, 1991, pp. 155-159.

Available in English only. Summary in German.

ABSTRACT: Radioprotector WR-2721 (S-2 (3-amino-propylamino)-ethyl-phosphorothioic acid) includes in vitro the contraction of DNA chains, but only when these originate from normal cells. Chain contraction results in a decrease of UV absorbance at 260 nm (hypochromicity). A correlation exists between DNA hypercromicity induced by WR-2721 and decrease in the synthesis of the same DNAs used as templates in the presence of this radioprotector. In contrast, the compound has no effect either on secondary structure of DNAs from various cancer cells or on in vitro synthesis of these DNAs. In association with R.L.B. which selectively prime replication of DNAs from normal haematopoietic cells, WR-2721, used at ralatively low doses, protects mice against lethal doses of gamma radiation. Efficient survival rates are obtained. The mechanism of this protection by WR-2721 and R.L.B. is discussed.

Download Radioprotection of Irradiated Mice – Mechanisms and Synergistic Action of WR-2721 and R.L.B.